breast-cancer

ADCs, immunotherapy, and targeted agents are reshaping triple-negative breast cancer treatment.

TNBC historically had few targeted options and the worst breast cancer outcomes. Recent advances include checkpoint inhibitors improving outcomes for PD-L1-positive metastatic disease, and ADCs (sacituzumab govitecan, trastuzumab deruxtecan) moving earlier in treatment algorithms. Molecular heterogeneity characterization is enabling more personalized approaches. Predictive biomarkers and optimal sequencing remain critical unmet needs.

Key Findings

TNBC has fewest targeted treatment options and worst outcomes among breast cancer subtypes
Checkpoint inhibitors improve outcomes in PD-L1-positive advanced TNBC
ADCs (sacituzumab govitecan, trastuzumab deruxtecan) are reshaping treatment landscape
ADCs moving earlier in treatment algorithms
Predictive biomarkers and optimal sequencing remain unmet needs

Implications

Oncologists should incorporate ADC options and PD-L1 testing into advanced TNBC management. Clinical trial enrollment is especially important.

Caveats

Review/educational article; abstract-only. Rapidly evolving field—recommendations may be superseded quickly.

Source: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting — 2026-06-01

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.